Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dendritic cell vaccination Clear all
Completed Phase 1Phase 2 Interventional

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

NCT00626860
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
DC/tumor fusion vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Early Phase 1 Interventional

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

NCT02851056
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13, Granulocyte-colony Stimulating Factor
Biological · Procedure · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 9, 2026, 1:52 AM EDT
Terminated Phase 1 Interventional Results available

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

NCT00843830
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma
Interventions
tumoral irradiation, Dendritic cell vaccination
Radiation · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00639639
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 9, 2026, 1:52 AM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 9, 2026, 1:52 AM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

NCT01456104
View directory record Official record
Conditions
Melanoma
Interventions
Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 9, 2026, 1:52 AM EDT
Active, not recruiting Phase 2 Interventional

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

NCT03384914
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

NCT01189383
View directory record Official record
Conditions
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Interventions
IL15-DC Vaccine
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT01957956
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide
Other · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 9, 2026, 1:52 AM EDT
Not listed Phase 1 Interventional

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

NCT00715832
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dendritic Cell Vaccination
Biological
Lead sponsor
Southern Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Sep 9, 2026, 1:52 AM EDT
Active, not recruiting Phase 1 Interventional

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

NCT03186118
View directory record Official record
Conditions
CD 19+ Acute Leukemia
Interventions
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 1:52 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00098917
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019214
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Results available

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT01995708
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

NCT00039325
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
dendritic cell-MART-1 peptide vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions
Dendritic Cells, Imiquimod
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

NCT01823978
View directory record Official record
Conditions
Castrate Resistent Prostate Cancer
Interventions
BPX-201 vaccine plus AP1903
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients

NCT02479230
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Joseph Baar, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 9, 2026, 1:52 AM EDT
Recruiting Early Phase 1 Interventional

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Leukapheresis, Dendritic Cell (DC) Vaccine
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Sep 9, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

NCT02018458
View directory record Official record
Conditions
Breast Cancer
Interventions
LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 9, 2026, 1:52 AM EDT